Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E–knockout mice

BMC Cardiovascular Disorders

Zhong-zhi Tang¹  Fang Chen³  Rong Ai²  Wei-hua Lu¹  Xiao-wei Wu⁴  Gang Li¹ 

[1] Emergency Department, Wuhan General Hospital of Guangzhou Military Command, Wuhan 430074, China;College of Foreign Language, Huazhong Agriculture University, Wuhan, China;Department of Medicine Laboratory, Wuhan General Hospital of Guangzhou Military Command, Wuhan, China;Department of Thoracic Surgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, China

关键词: Inflammation;    Gamma-glutamyltransferase;    Atherosclerosis;    Statins;   

Others  :  1088429
DOI  :  10.1186/1471-2261-14-145

 received in 2014-08-02, accepted in 2014-10-10,  发布年份 2014

【 摘 要 】

Background

Gamma-glutamyl transpeptidase (GGT) is now considered to be one of the risk factors for cardiovascular disease. However, whether statins can alter GGT levels in arterial atheromatous plaque has not yet been studied. Therefore, the aim of this study is to determine whether statins can effectively decrease the expression of GGT in arterial atheromatous plaques.

Methods

We randomly divided 45 apolipoprotein E–knockout (ApoE KO) male mice into three groups: normal diet (ND) group,high-cholesterol diet (HCD) group and high-cholesterol diet and atorvastatin (HCD + Ato) group. We fed high-cholesterol food to the HCD and HCD + Ato group. After eight weeks, atorvastatin 5 mg•kg⁻¹•d⁻¹ was given to HCD + Ato group mice. The serum GGT-1, intercellular cell adhesion molecule-1 (ICAM-1) and vascular cell-adhesion molecule-1 (VCAM-1) levels were measured at end of 16 weeks by using ELISA methods. The expressions of GGT-1, ICAM-1 and VCAM-1 in aorta were measured by RT-PCR and Western Blot.

Results

The ApoE KO mice with HCD were associated with a marked increase in plasma lipid, inflammatory factors, GGT-1, ICAM-1 and VCAM-1. The expressions of GGT-1, ICAM-1 and VCAM-1 in HCD aortic tissue were increased. At the HCD + Ato group were treated with atorvastatin, the levels of lipid, GGT-1, ICAM-1 and VCAM-1were suppressed. Meanwhile, the expressions of GGT-1, ICAM-1 and VCAM-1 were significantly decreased in the whole aorta plaques.

Conclusions

The effect of statins on the expression of GGT in aorta plaque was firstly observed in animal model. The research shows that statins can significantly decrease the expression of GGT in aortic atherosclerotic plaques.

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Zhao S, Yu B, Peng D, Huo Y: The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial. Atherosclerosis 2014, 233:707-712.
• [2]Reiner Ž, De Bacquer D, Kotseva K, Prugger C, Backer De G, Wood D: Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis 2013, 231:300-307.
• [3]Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP: Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010, 376:1916-1922.
• [4]Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, Antonopoulos AS, Demosthenous M, Marinou K, Hale A, Paschalis A, Psarros C, Triantafyllou C, Bendall J, Casadei B, Stefanadis C, Channon KM: Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011, 124:335-345.
• [5]Schmidt-Lucke C, Fichtlscherer S, Rössig L, Kämper U, Dimmeler S: Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis 2010, 211:249-254.
• [6]Elewa HF, El‒Remessy AB, Somanath PR, Fagan SC: Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy. J Human Pharmacol Drug Ther 2010, 30:169-176.
• [7]Jain MK, Ridker PM: Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005, 4:977-987.
• [8]Trialists CT: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
• [9]Sampson UK, Fazio S, Linton MRF: Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012, 14:1-10.
• [10]Mason JE, Starke RD, Van Kirk JE: Gamma‒Glutamyl transferase: a novel cardiovascular risk BioMarker. Prev Cardiol 2010, 13:36-41.
• [11]Gül M, Uyarel H, Ergelen M, Ekmekci A, Özal E, Murat A, Kul S, Çelik O, Karaca G, Akturk F, Eksik A: The relationship between gamma glutamyl transferase levels and the clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary PCI. J Am Coll Cardiol 2013, 62:C215-C215.
• [12]Grundy SM: Gamma-glutamyl transferase another biomarker for metabolic syndrome and cardiovascular risk. Arterioscler Thromb Vasc Biol 2007, 27:4-7.
• [13]Lee DH, Blomhoff R, Jacobs DR: Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 2004, 38:535-539.
• [14]Giral P, Ratziu V, Couvert P, CarriR A, Kontush A, Girerd X, Chapman MJ: Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. Atherosclerosis 2010, 210:607-613.
• [15]Paolicchi A, Emdin M, Ghliozeni E, Ciancia E, Passino C, Popoff G, Pompella A: Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation 2004, 109:1440.
• [16]Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. FASEB J 2007, 22:659-661.
• [17]Emdin M, Pompella A, Paolicchi A: Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease triggering oxidative stress within the plaque. Circulation 2005, 112:2078-2080.
• [18]Galli E, Mariani M, Botto N, Paradossi U, Cardullo S, Taddei A, Storti S, Clerico A, Emdin M, Berti S, Galli E: Gamma-glutamyltransferase levels as a predictor of mortality in patients with ST-elevation myocardial infarction. Eur Heart J 2013, 34:P5565.
• [19]Du G, Song Z, Zhang Q: Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: a meta-analysis of prospective cohort studies. Prev Med 2013, 57:31-37.
• [20]Maria F, Alessandro C, Barbara M, Antonella DC: γ-Glutamyltransferase activity in human atherosclerotic plaques—biochemical similarities with the circulating enzyme. Atherosclerosis 2009, 202:119-127.
• [21]Demircan S, Yazici M, Durna K, Kilicaslan F, Demir S, Pinar M, Gulel O: The importance of gamma glutamyltransferase activity in patients with coronary artery disease. Clin Cardiol 2009, 32:220-225.
• [22]Aksakal E, Tanboga IH, Kurt M, Kaygyg MA, Kaya A, Isik T, Ekinci M, Sevimli S, Acikel M: The relation of serum gamma-glutamyl transferase levels with coronary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis 2012, 221:596-601.
• [23]Cakar M, Balta S, Demirkol S, Altun B, Demirbas S: Serum gamma-glutamyltransferase (GGT) should be evaluated together with other inflammatory markers in clinical practice. Angiology 2013, 64:401-401.
• [24]Paolicchi A, Emdin M, Passino C, Lorenzini E, Titta F, Marchi S, Malvaldi G, Pompella A: β-Lipoprotein- and LDL-associated serum γ-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis 2006, 186:80-85.
• [25]Sun J, Ren J, Pang ZC, Gao WG, Nan HR, Wang SJ, Zhang L, Qiao Q: The association of gamma-glutamyltransferase and C-reactive protein with IFG/IGT in Chinese adults in Qingdao, China. Clin Chim Acta 2011, 412:1658-1661.
• [26]Bradley RD, Fitzpatrick AL, Jacobs DR Jr, Lee DH, Jenny NS, Herrington D: Associations between γ-glutamyltransferase (GGT) and biomarkers of atherosclerosis: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2014, 233:387-393.
• [27]Woollard KJ, Geissmann F: Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010, 7:77-86.
• [28]Schmitz B, Vischer P, Brand E, Schmidt-Petersen K, Korb-Pap A, Guske K, Nedele J, Schelleckes M, Hillen J, Rötrige A, Simmet T, Paul M, Cambien F, Brand SM: Increased monocyte adhesion by endothelial expression of VCAM-1 missense variation in vitro. Atherosclerosis 2013, 230:185-190.
• [29]Yang JCS, Huang F, Wu CJ, Chen YC, Lu TH, Hsieh CH: Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide. Inflamm Res 2012, 61:485-491.
• [30]Chung HK, Lee IK, Kang H, Suh JM, Kim H, Park KC, Kim DW, Kim YK, Ro HK, Shong MH: Statin inhibits interferon-γ-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 2002, 34:451-461.